Sage therapeutics, inc. (SAGE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net loss

-126,740

-168,653

-179,958

-168,221

-163,406

-158,388

-122,918

-16,978

-74,598

-69,422

-73,719

-70,201

-56,778

-55,901

-37,796

-34,747

-30,543

-28,562

-24,035

-25,027

-16,871

-12,361

-9,468

-6,192

-5,790

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

31,110

30,679

43,669

34,767

44,116

31,640

25,478

29,028

15,817

10,245

9,731

9,350

6,208

10,093

4,748

4,465

3,714

4,086

4,407

5,398

1,349

1,326

691

335

160

Non-cash licensing and consulting fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

787

424

0

0

0

127

Premium on marketable securities

240

1,022

765

1,148

739

50

90

71

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discount on marketable securities

18

537

1,456

2,651

2,322

2,991

2,747

2,806

1,348

236

62

28

-33

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

700

700

680

520

400

300

307

246

247

104

136

130

130

82

83

75

41

32

29

32

22

16

13

11

11

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,221

-3,713

3,392

6,739

-1,637

3,191

-12,820

19,743

5,348

1,335

-301

-1,287

1,380

1,682

1,606

-1,115

1,189

-867

-671

2,085

134

-7

287

383

52

Other long-term assets

-99

-25

-205

2,645

1,378

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use operating asset

-1,778

-1,744

-1,711

-1,771

-2,942

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, current

25

-

-

-

-156

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, non-current

-1,897

-

-

-

-2,344

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-7,307

10,172

-7,149

-1,299

-20,507

27,914

-2,467

-26

-877

-3,914

6,989

-2,125

-4,643

7,680

-825

1,740

-799

1,782

-1,952

2,417

343

447

379

86

-471

Accrued expenses and other liabilities

-35,391

8,312

19,522

14,162

-8,192

2,925

9,450

10,215

-12,460

5,684

10,581

2,511

1,220

5,846

4,920

937

1,341

3,678

1,365

35

261

1,898

1,186

870

399

Net cash used in operating activities

-136,691

-116,726

-128,702

-133,344

-149,934

-101,778

-80,187

-135

-78,571

-58,899

-46,092

-59,076

-55,210

-33,776

-30,796

-26,671

-27,435

-18,117

-19,515

-18,443

-14,606

-8,667

-7,486

-5,273

-5,616

Proceeds from sales and maturities of marketable securities

275,197

213,430

369,188

281,389

307,263

250,625

460,672

181,500

81,960

46,789

104,000

59,683

50,753

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

68,651

230,973

159,469

337,317

580,916

211,399

459,622

419,228

394,109

150,587

59,894

15,014

18,908

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

276

373

1,940

2,181

1,257

808

998

402

652

804

235

76

245

520

66

494

341

38

-21

71

110

45

78

2

3

Net cash provided by (used in) investing activities

206,270

-17,916

207,779

-58,109

-274,910

38,418

52

-238,130

-312,801

-104,602

43,871

44,593

31,600

-117,938

-27,720

-84,016

-341

-38

21

-71

-110

-45

-78

-2

-3

Cash flows from financing activities
Proceeds from stock option exercises and employee stock purchase plan issuances

3,160

2,166

15,402

15,601

15,681

1,628

8,078

6,645

12,757

8,974

3,687

2,758

553

678

416

10

302

67

227

289

147

-

-

-

-

Payment of employee tax obligations related to vesting of restricted stock units

-

0

1,483

0

692

0

0

0

904

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of offering costs

-

0

0

258

70

0

0

105

235

-

-

-

-

0

0

0

599

36

90

423

35

-

-

-

-

Proceeds from public offerings of common stock, net of commissions and underwriting discounts

-

0

0

0

561,277

0

0

0

631,494

-

-

-

-

0

189,175

0

141,000

-

-

-

-

0

96,253

0

2

Net cash provided by financing activities

3,160

2,166

13,919

15,343

576,196

1,628

8,078

6,540

643,112

334,820

3,687

2,758

553

678

189,591

10

140,703

31

137

129,586

112

-249

95,164

-1,023

52,978

Net increase in cash, cash equivalents and restricted cash

72,739

-132,476

92,996

-176,110

151,352

-61,732

-72,057

-231,725

251,740

171,319

1,466

-11,725

-23,057

-151,036

131,075

-110,677

112,927

-18,124

-19,357

111,072

-14,604

-8,961

87,600

-6,298

47,359

Supplemental disclosure of non-cash operating and investing activities
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

391

1,577

326

Purchases of property and equipment included in accounts payable

15

54

-241

174

78

32

9

-5

15

-

-

-

64

-

-

-

279

-

-

-

-

-

-

-

-

Public offering costs included in accounts payable

-

-

-

-

259

-

-

-

105

-

-

-

-

-

-

-

-

161

-133

-14

151

-

-

-

-

Deferred public offering costs included in accounts payable or accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

842